Table 5.
Prognostic factors related with improved progression-free and overall survivals in 109 patients with ovarian clear cell carcinoma
| Factor | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | |
| Progression-free survival | ||||||
| Age < 54 yr | 1.14 | 0.60-2.17 | 0.68 | - | - | - |
| FIGO stage I-II disease | 0.15 | 0.08-0.31 | < 0.01 | 0.18 | 0.08-0.41 | < 0.01 |
| Pure OCCC | 0.56 | 0.20-1.59 | 0.28 | - | - | - |
| Optimal debulking | 0.13 | 0.06-0.27 | < 0.01 | 0.37 | 0.16-0.84 | 0.02 |
| Taxane- and platinum-based chemotherapy | 0.87 | 0.41-1.84 | 0.72 | 0.36 | 0.15-0.89 | 0.03 |
| > 6 cycles of chemotherapy | 1.79 | 0.82-3.93 | 0.14 | - | - | - |
| NLR < 2.8 | 0.34 | 0.18-0.67 | < 0.01 | 0.49 | 0.25-0.99 | 0.04 |
| CA-125 < 68.5 (U/mL) | 0.29 | 0.15-0.57 | < 0.01 | - | - | - |
| Overall survival | ||||||
| Age < 54 yr | 2.00 | 0.85-4.69 | 0.11 | - | - | - |
| FIGO stage I-II disease | 0.12 | 0.05-0.30 | < 0.01 | 0.08 | 0.03-0.22 | < 0.01 |
| Pure OCCC | 0.53 | 0.16-1.78 | 0.30 | - | - | - |
| Optimal debulking | 0.14 | 0.06-0.36 | < 0.01 | 0.26 | 0.09-0.75 | 0.01 |
| Taxane- and platinum-based chemotherapy | 0.69 | 0.29-1.65 | 0.40 | - | - | - |
| > 6 cycles of chemotherapy | 3.06 | 1.31-7.13 | 0.10 | - | - | - |
| NLR < 2.8 | 0.29 | 0.13-0.68 | < 0.01 | - | - | - |
| CA-125 < 68.5 (U/mL) | 0.26 | 0.11-0.59 | < 0.01 | - | - | - |
HR, hazard ratio; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; OCCC, ovarian clear cell carcinoma; NLR, neutrophil to lymphocyte ratio; CA-125, cancer antigen 125.